Institut Català de la Salut
[Garcia C, Vidal-Taboada JM] Unitat Esclerosi Lateral Amiotròfica (ELA), Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Barcelona, Spain. [Syriani E, Morales M] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Barcelona, Spain. [Salvado M, Gamez J] Unitat Esclerosi Lateral Amiotròfica (ELA), Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-04-09T11:01:21Z
2021-04-09T11:01:21Z
2019-11-08
A4V; SOD1; Esclerosi lateral amiotròfica
A4V; SOD1; Esclerosis lateral amiotrófica
A4V; SOD1; Amyotrophic lateral sclerosis
Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population.
This study has been supported by Instituto de Salud Carlos III (grant numbers PIS-FEDER PI16/01673 and PI19/00593). JG and JV-T are the recipients of grant 2017SGR00939 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya.
Article
Published version
English
Esclerosi lateral amiotròfica; Superòxid dismutasa; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Spinal Cord Diseases::Amyotrophic Lateral Sclerosis; CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Superoxide Dismutase::Superoxide Dismutase-1; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades de la médula espinal::esclerosis lateral amiotrófica; COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::oxidorreductasas::superóxido dismutasa::superóxido dismutasa-1
Frontiers Media
Frontiers in Genetics;10
https://www.frontiersin.org/article/10.3389/fgene.2019.01109/full
info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F01673
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00593
info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR00939
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1664]